← United States · All US Insider Profiles
US INSIDER PROFILE · NON-SCORING RESEARCH
Ng George K
Chief Executive Officer | Officer
Identity: SEC reporting-owner CIK · Reporting-owner CIK: 0001638744
Purchase history
- Companies traded
- 1
- Purchases · 12M
- 8
- Purchases · 24M
- 9
- Average purchase
- $12.7K
- Median purchase
- $5.5K
- Gross purchase value
- $114.0K
Companies: Processa Pharmaceuticals, Inc.
9 SEC accession(s) · 0 joint-owner event(s). Values are reported Form 4 transaction values in USD.
Qualifying purchase disclosures
| Published | Company | Ticker | Role | Reported value | SEC source |
|---|---|---|---|---|---|
| 2026-07-01 | Processa Pharmaceuticals, Inc. | PCSA | Chief Executive Officer | Officer | $5.9K | Open filing |
| 2026-06-16 | Processa Pharmaceuticals, Inc. | PCSA | Chief Executive Officer | Officer | $5.5K | Open filing |
| 2026-06-01 | Processa Pharmaceuticals, Inc. | PCSA | Chief Executive Officer | Officer | $5.5K | Open filing |
| 2026-05-19 | Processa Pharmaceuticals, Inc. | PCSA | Chief Executive Officer | Officer | $5.5K | Open filing |
| 2026-05-19 | Processa Pharmaceuticals, Inc. | PCSA | Chief Executive Officer | Officer | $5.5K | Open filing |
| 2026-05-01 | Processa Pharmaceuticals, Inc. | PCSA | Chief Executive Officer | Officer | $5.5K | Open filing |
| 2026-04-30 | Processa Pharmaceuticals, Inc. | PCSA | Chief Executive Officer | Officer | $5.5K | Open filing |
| 2026-04-17 | Processa Pharmaceuticals, Inc. | PCSA | Chief Executive Officer | Officer | $5.5K | Open filing |
| 2025-01-29 | Processa Pharmaceuticals, Inc. | PCSA | Chief Executive Officer | Officer | $69.8K | Open filing |
Post-purchase outcomes
Excess return = stock return − S&P 500 ETF (SPY adjusted close) return. Returns start on the first shared trading session on or after publication.
| Period | Completed events | Price coverage | Hit rate | Median excess return | Average excess return | Worst excess return |
|---|---|---|---|---|---|---|
| 5D | 9Developing | 100.0% (9/9) | 33.3% (3/9) | -1.8% | -2.6% | -10.7% |
| 20D | 9Developing | 100.0% (9/9) | 22.2% (2/9) | -8.6% | -8.9% | -22.8% |
| 60D | 9Developing | 100.0% (9/9) | 11.1% (1/9) | -13.0% | -16.5% | -51.7% |
| 120D | 2Small Sample | 100.0% (2/2) | 0.0% (0/2) | -65.6% | -65.6% | -66.0% |
Research patterns
- First purchase in 12M
- 1/8
- Large purchase ≥ $100k
- 0/9
- Cluster buying · 15D
- 9/9
- Buying the dip
- 9/9
Routine / opportunistic: Not classifiable. These labels never affect the score or ranking.
Small samples remain visible but are not scored. This research enrichment never affects US-v1.1.